全文获取类型
收费全文 | 14362篇 |
免费 | 791篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 175篇 |
儿科学 | 239篇 |
妇产科学 | 84篇 |
基础医学 | 1467篇 |
口腔科学 | 330篇 |
临床医学 | 936篇 |
内科学 | 3868篇 |
皮肤病学 | 241篇 |
神经病学 | 1003篇 |
特种医学 | 570篇 |
外科学 | 2712篇 |
综合类 | 60篇 |
预防医学 | 315篇 |
眼科学 | 264篇 |
药学 | 1038篇 |
中国医学 | 64篇 |
肿瘤学 | 1904篇 |
出版年
2023年 | 77篇 |
2022年 | 72篇 |
2021年 | 355篇 |
2020年 | 225篇 |
2019年 | 316篇 |
2018年 | 406篇 |
2017年 | 292篇 |
2016年 | 376篇 |
2015年 | 393篇 |
2014年 | 467篇 |
2013年 | 554篇 |
2012年 | 869篇 |
2011年 | 1025篇 |
2010年 | 556篇 |
2009年 | 435篇 |
2008年 | 809篇 |
2007年 | 917篇 |
2006年 | 864篇 |
2005年 | 898篇 |
2004年 | 879篇 |
2003年 | 872篇 |
2002年 | 833篇 |
2001年 | 294篇 |
2000年 | 239篇 |
1999年 | 220篇 |
1998年 | 156篇 |
1997年 | 135篇 |
1996年 | 121篇 |
1995年 | 119篇 |
1994年 | 100篇 |
1993年 | 84篇 |
1992年 | 106篇 |
1991年 | 115篇 |
1990年 | 108篇 |
1989年 | 116篇 |
1988年 | 103篇 |
1987年 | 80篇 |
1986年 | 75篇 |
1985年 | 79篇 |
1984年 | 47篇 |
1983年 | 64篇 |
1982年 | 35篇 |
1981年 | 38篇 |
1980年 | 25篇 |
1979年 | 46篇 |
1978年 | 36篇 |
1977年 | 41篇 |
1973年 | 24篇 |
1972年 | 23篇 |
1971年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
ObjectivesEosinophilic otitis media (EOM) is an intractable otitis media mostly associated with bronchial asthma. Dupilumab, an anti-interleukin (IL)-4 receptor (R)α, is effective and has been approved for use in patients with moderate to severe bronchial asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis, whose diseases are not controlled by previous treatments including other molecular targeted drugs. We aimed to assess efficacy of dupilumab in three EOM patients with associated bronchial asthma, who were poor responders to previous topical and systemic corticosteroid therapy and molecular targeted therapies.Patients and methodsThree patients with severe, refractory EOM (two with a granulation type) associated with bronchial asthma received dupilumab as add-on therapy for at least 6 months. The efficacy of dupilumab therapy was evaluated using severity scores, symptom scores, hearing acuities, temporal bone computed tomography (CT) scores, and surrogate markers before and after therapy.ResultsSeverity scores in all patients were dramatically reduced to 2 points or less (full score: 16 points) after initiation of therapy. Air conduction hearing levels were improved in all patients. Temporal bone CT scores in two patients were reduced, and serum IgE levels in all three patients also decreased following therapy.ConclusionWe provide the first report that add-on dupilumab therapy was effective in patients with severe, refractory EOM who did not respond to the treatments including other molecular targeted therapy. Patients with severe middle ear mucosal change may benefit particularly from dupilumab therapy. 相似文献
2.
3.
Masaru Sasaki Tsuyoshi Takahashi Soichiro Funaki Koji Tanaka Yasuhiro Miyazaki Naoko Ose Tomoki Makino Yukinori Kurokawa Makoto Yamasaki Kiyokazu Nakajima Yasushi Shintani Masaki Mori Yuichiro Doki 《Asian journal of endoscopic surgery》2021,14(1):116-119
We report a case of a diaphragmatic hernia after a heart transplant operation. A 43-year-old woman, who underwent orthotropic heart transplantation for hypertrophic cadiomyopathy two year earlier, presented with vomiting and epigastric pain. A computed tomography scan showed that the stomach and transverse colon were dislocated in the left thoracic cavity. We diagnosed left diaphragmatic hernia incarceration and performed laparoscopic repair of the diaphragmatic hernia. A 12 × 8 cm diaphragmatic defect was found intraoperatively on the ventrolateral aspect of the left diaphragm, and the stomach with volvulus had herniated into the thorax through the defect. The hernia was considered to be iatrogenic. The diaphragmatic defect was large, and the diaphragm was thinning. We closed the defect by mesh repair. Laparoscopic mesh repair of the diaphragmatic hernia could be performed safely and with minimal invasiveness. 相似文献
4.
5.
6.
7.
Takeshi Nagashima Ken Yamaguchi Kenichi Urakami Yuji Shimoda Sumiko Ohnami Keiichi Ohshima Tomoe Tanabe Akane Naruoka Fukumi Kamada Masakuni Serizawa Keiichi Hatakeyama Kenya Matsumura Shumpei Ohnami Koji Maruyama Tohru Mochizuki Masatoshi Kusuhara Akio Shiomi Yasuhisa Ohde Masanori Terashima Katsuhiko Uesaka Tetsuro Onitsuka Seiichiro Nishimura Yasuyuki Hirashima Nakamasa Hayashi Yoshio Kiyohara Yasuhiro Tsubosa Hirohisa Katagiri Masashi Niwakawa Kaoru Takahashi Hiroya Kashiwagi Masahiro Nakagawa Yuji Ishida Takashi Sugino Mitsuru Takahashi Yasuto Akiyama 《Cancer science》2020,111(2):687-699
This study aimed to establish the Japanese Cancer Genome Atlas (JCGA) using data from fresh frozen tumor tissues obtained from 5143 Japanese cancer patients, including those with colorectal cancer (31.6%), lung cancer (16.5%), gastric cancer (10.8%) and other cancers (41.1%). The results are part of a single‐center study called “High‐tech Omics‐based Patient Evaluation” or “Project HOPE” conducted at the Shizuoka Cancer Center, Japan. All DNA samples and most RNA samples were analyzed using whole‐exome sequencing, cancer gene panel sequencing, fusion gene panel sequencing and microarray gene expression profiling, and the results were annotated using an analysis pipeline termed “Shizuoka Multi‐omics Analysis Protocol” developed in‐house. Somatic driver alterations were identified in 72.2% of samples in 362 genes (average, 2.3 driver events per sample). Actionable information on drugs that is applicable in the current clinical setting was associated with 11.3% of samples. When including those drugs that are used for investigative purposes, actionable information was assigned to 55.0% of samples. Germline analysis revealed pathogenic mutations in hereditary cancer genes in 9.2% of samples, among which 12.2% were confirmed as pathogenic mutations by confirmatory test. Pathogenic mutations associated with non–cancerous hereditary diseases were detected in 0.4% of samples. Tumor mutation burden (TMB) analysis revealed 5.4% of samples as having the hypermutator phenotype (TMB ≥ 20). Clonal hematopoiesis was observed in 8.4% of samples. Thus, the JCGA dataset and the analytical procedures constitute a fundamental resource for genomic medicine for Japanese cancer patients. 相似文献
8.
9.
10.
Morihito Okada Yoshihiro Miyata Kazuya Takamochi Yasuhiro Tsutani Shiaki Oh Kenji Suzuki 《The Journal of thoracic and cardiovascular surgery》2019,157(1):388-395